APGE

Apogee Therapeutics

Fundamental data last updated:April 13, 2026

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/11/26

Business Summary

Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologic therapies, most likely targeting high-value disease areas where pricing power and differentiation can be substantial. The business model is capital intensive upfront—funding research, trials, and regulatory approval—before any meaningful revenue materializes. Cash generation, if successful, would come from approved drug commercialization or strategic licensing partnerships with larger pharmaceutical players. Its moat, if achieved, would rest on proprietary molecules, clinical data exclusivity, and regulatory barriers that prevent generic competition for extended periods.

VALUATION

P/E

-

Market Cap ($M USD)

$6,435

Forward P/E

-

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

7.1

EV / EBITDA

-20.1

5-Year Average P/E

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$4.22

Next Year EPS Growth Estimate

-$5.45

Next Year Revenue Growth Estimate

-

Return on Equity (ROE)

-28.30%

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

3

Altman Z-Score

115.2

Return on Invested Capital (ROIC)

-34.10%%

Current Ratio

26.6

Quick Ratio

Gainseekers Quantitative Analysis

Summary

At a $6,435M market cap with no P/E, no Forward P/E, and EPS at -20.1, this is a pure balance-sheet-and-optionality story rather than an earnings-driven valuation. The absence of profitability metrics combined with a deeply negative ROIC of -34.10% and operating margin of -28.30% confirms the business is currently destroying capital. However, the Altman Z-Score of 115.2 and a massive 26.6 current ratio signal an unusually strong liquidity position and negligible near-term bankruptcy risk, effectively giving the company a long runway despite losses. This is not mispriced on earnings—there are none—but the market is clearly valuing cash strength and pipeline optionality over fundamentals.

AI Exposure / Tech Reliance

As a Biotechnology company within Healthcare, its future relevance depends heavily on data-driven drug discovery, clinical analytics, and precision medicine platforms. The sector is structurally aligned with AI-enabled target identification and trial optimization, which can materially compress development timelines and reduce burn rates. However, there is no financial evidence yet—given the negative margins and ROIC—that technological leverage has translated into economic efficiency.

The Bull Case

A GARP or deep-value investor would focus on the fortress-like balance sheet implied by the 26.6 current ratio and extraordinary 115.2 Altman Z-Score, which dramatically reduce insolvency risk despite heavy losses. Institutional ownership at 116.87% signals strong professional sponsorship and potential long-term conviction from sophisticated capital allocators. While operating margin sits at -28.30% and ROIC at -34.10%, biotech investors often underwrite future inflection rather than current returns, and the Piotroski F-Score of 3, while weak, leaves room for operational improvement from a low base. With zero dividend burden and no payout ratio pressure, all capital can be redeployed into R&D, giving patient investors exposure to asymmetric clinical upside without balance sheet stress.

The Bear Case

The bear case is straightforward: this is a cash-burning biotech with EPS at -20.1 and expected EPS next year still negative at -4.22, meaning profitability is not even remotely visible. Operating margin of -28.30% and ROIC of -34.10% confirm that capital deployed today generates deeply negative returns. There is no P/E, no Forward P/E, and no PEG ratio to anchor valuation discipline, making the $6,435M market cap difficult to justify on fundamentals alone. A Piotroski F-Score of 3 indicates weak financial quality, and with no disclosed Debt/Equity or Short % of Float data, investors lack transparency into leverage dynamics and bearish positioning risks.

Market Sentiment & Smart Money

Short Interest %

23.20%

Analyst Consensus

1.44

Average Analyst Price Target

$116.87

Institutional Ownership %

121.00%

1-Year Beta

1.38

Insider Buying % (6 Mo)

5.50%%

Distance to 52-Week High

97.70%%

Distance to 52-Week Low

301.60%%